Request Discount

Oral Vaccine Market (Type - Attenuated, Inactive, and Others; Application - Polio, Rabies, Tuberculosis, Respiratory Infection, HIV, and Cholera; End User - Hospitals, and Clinics): Global Industry Analysis, Trends, Size, Share and Forecasts to 2025

  • Published : December, 2019

  • Rep Id : HC0775

  • Category : Healthcare & Medical Devices

  • Status : Published

This report provides exclusive insights into the COVID-19 impact on the Oral Vaccine Market. The detailed analysis provides information about the impact of the outbreak on the demand and supply conditions, trends and forecasts of the Oral Vaccine Market. Moreover, the impact analysis covers the study of the COVID-19 on the supply chain of Oral Vaccine Market. The sectoral impact shall provide insights into both short term and long term effects of the pandemic on the related and support industries.

A recent report published by Infinium Global Research on the oral vaccine market provides an in-depth analysis of segments and sub-segments in the global as well as regional oral vaccine market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional oral vaccine market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of the global oral vaccine market. According to the report, the global oral vaccine market is projected to grow at a CAGR of 7.2% over the forecast period of 2019-2025.


Market Insight

The demand for oral vaccines is rising rapidly as they are safe and easy to administer. It is convenient for all ages. It protects from many infectious diseases acquired through oral transmission. It is cost-effective. There are different types of oral poliovirus vaccine which may contain one, a combination of two or all three different serotypes of the attenuated vaccine. Oral delivery of vaccine represents the foremost enticing mode of administration over other routes of delivery. The oral vaccine is used against many diseases such as polio, typhoid, and cholera. Rotavirus and Rota Teq are two currently used oral vaccines which protect against rotavirus gastroenteritis. Rotavirus and Rota Teq protection can reach 85% to 100% to prevent severe rotavirus gastroenteritis. As of April 2019, no oral vaccines are available for the Zika virus. However, the number of vaccines are currently in clinical trials.


The rising prevalence of infectious diseases in developing countries is the factor driving the growth of the oral vaccine market. Elimination of needles in the vaccination process and their safe and cost-effective nature are the factors propelling the oral vaccine market. Growing government support for an oral vaccine is boosting the oral vaccine market. The growing availability of funding for vaccine R&D is the factor enhancing the oral vaccine market. However, the storage and distribution cost of the vaccine is higher than any other pharmaceutical product, as it requires specialized equipment and monitoring devices. The lack of proper storage and distribution facilities can deteriorate vaccine quality. Thus, the high cost of vaccine development and storage remains one of the major restraints to the growth of the oral vaccine market. Adjuvants are used for increasing the efficacy of vaccines. Companies are researching new adjuvant combinations and novel immunomodulatory molecules to enhance antigen-specific protection from diseases, such as cancer, hepatitis, HIV. Thus, the use of adjuvant in vaccines offers favorable opportunities for the oral vaccine market.


Geographically, North America is the dominant region in the oral vaccine market. Recent USFDA approvals for oral vaccines for infectious diseases such as tuberculosis & cholera and periodical mass immunization programs held by the government drive the oral vaccine market in North America. Europe holds the second largest market share in the oral vaccine market. Factors such as availability of funding & venture capital investments for the development of new vaccines and increasing government initiatives are expected to drive market growth in the Europe region. Asia Pacific is expected to grow with the highest CAGR in the oral vaccine market. Rising incidence of HIV and influenza drives the oral vaccine market in the Asia Pacific. Also, increasing investments by companies in emerging countries, such as India and China is contributing to the growth of the market


Segment Covered

The report on the global oral vaccine market covers segments such as type, application, and end user. On the basis of type, the sub-markets include attenuated, inactive, and others. On the basis of application, the sub-markets include polio, rabies, tuberculosis, respiratory infection, HIV, and cholera. On the basis of end user, the sub-markets include hospitals, and clinics.


Companies Profiled:

The report provides profiles of the companies in the market such as GlaxoSmithKline plc, Merck & Co., Inc., QUÍMICA SUIZA S.A., PaxVax Corporation, Serum Institute of India Pvt. Ltd., and Shanghai BravoBio Co., Ltd.


Report Highlights:

The report provides deep insights into the demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of the oral vaccine market. Moreover, the study highlights current market trends and provides forecast from 2019-2025. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.

Other Reports in This Category
24 hour delivery through email
9923950043 Monday to Frieday 9am-7pm
looking for discount